FDA addresses accessibility to CBD, it's benefits

As the world continues to adjust to the threat of the Coronavirus, a push is made for accessibility to CBD because of the health benefits it could have on the populace.

In a recent report from the FDA directed to Congress to discuss CBD and how it affects the industry, “the FDA recognized the difference between full-spectrum extracts, broad-spectrum extracts, and CBD isolate for the first time, acknowledging that all three products can produce different effects and need to be studied independently.”

This is an issue close to Florida as Florida leadership has backed support for decriminalizing hemp. 

Since last year, the House has been pressed to respond to the concerns of its citizens who could benefit from the use of CBD.

In the report, the FDA “discussed providing more transparency in their enforcement policy, meaning they will be forthright in the criteria they use to determine which CBD companies pose risks to consumers and should be subject to enforcement.”

The FDA will next report to Congress “in the summer, so companies will likely be waiting for some time on how to market CBD as a dietary supplement.”

Rep. Matt Gaetz (R) has been one of the strongest supporters of legalizing and using Hemp and marijuana for medical purposes.